Table 1.
Main clinical and cancer-related characteristics of patients with active cancer treatment admitted due to COVID19 infection.
| Demographics | All patients (N = 63) | ||
|---|---|---|---|
| Age | <50 years | 4 (6%) | |
| 50–70 years | 36 (57%) | ||
| >70 years | 23 (37%) | ||
| Sex | Male | 34 (54%) | |
| Female | 29 (46%) | ||
| Race | Caucasian | 54 (86%) | |
| Latin American | 4 (6%) | ||
| Others | 5 (8%) | ||
| Smoking history |
Never smoker | 29 (46%) | |
| Former smoker | 27 (43%) | ||
| Current smoker |
7 (11%) |
||
| Comorbidities |
No |
Yes |
|
| Previous anaemia | 53 (84%) | 10 (16%) | |
| Hypertension | 30 (48%) | 33 (52%) | |
| Diabetes | 52 (83%) | 11 (17%) | |
| Chronic kidney disease | 58 (92%) | 5 (8%) | |
| Cardiopathy | 51 (80%) | 12 (19%) | |
| Chronic pulmonary disease | 49 (78%) | 14 (22%) | |
| Previous VTED | 50 (79%) | 13 (21%) | |
| ACEi/ARBs treatment | 53 (84%) | 10 (16%) | |
| Anticoagulant therapy | 50 (79%) | 13 (21%) | |
| Chronic corticosteroids | 48 (76%) | 15 (24%) | |
| >10 mg | NA |
12 (19%) | |
| <10 mg |
3 (5%) |
||
| Cancer-related characteristics |
No |
Yes |
|
| Metastatic disease | 11(18%) | 52(82%) | |
| Oligometastatic | NA | 36 (57%) | |
| Polymetastatic | 16 (25%) | ||
| Tumour pulmonary involvement | 38 (60%) | 25 (40%) | |
| Active cancer treatment | 2 (4%) | 61 (96%) | |
| Chemotherapy | NA | 36 (58%) | |
| Endocrine | 10 (15%) | ||
| Target therapy | 7 (11%) | ||
| I mmunotherapy | 8 (12%) | ||
Numbers are expressed as n (%).
VTE, venous thromboembolic disease; ACEi/ARBs, angiotensin converting enzyme inhibitor/angiotensin receptor blockers.